BUZZ-Evotec seen up on 2 bln euro buyout offer from Halozyme

Reuters

Nov 15, 2024

** German drug development company Evotec are seen up around 20% in Lang&Schwarz premarket indications after biotech company Halozyme made a 2 billion euro($2.11 billion) buyout offer to the company

** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price

** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout

** The news on Halozyme might spark a takeover battle, a local trader said

** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps

($1 = 0.9493 euros)

(Reporting by Isabel Demetz)

((Isabel.demetz@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483164323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483164323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483164323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483164323","market":"us","top_or_hot":-1,"title":"BUZZ-Evotec seen up on 2 bln euro buyout offer from Halozyme","media":"Reuters","content":"<html><body><p>** German drug development company Evotec    are seen up around 20% in Lang&amp;Schwarz premarket indications after biotech company Halozyme    made a 2 billion euro($2.11 billion) buyout offer to the company</p><p>   ** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price</p><p>   ** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout</p><p>   ** The news on Halozyme might spark a takeover battle, a local trader said</p><p>   ** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps</p><p>($1 = 0.9493 euros)</p><p> (Reporting by Isabel Demetz)</p><p>((Isabel.demetz@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Evotec seen up on 2 bln euro buyout offer from Halozyme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Evotec seen up on 2 bln euro buyout offer from Halozyme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-15 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** German drug development company Evotec    are seen up around 20% in Lang&amp;Schwarz premarket indications after biotech company Halozyme    made a 2 billion euro($2.11 billion) buyout offer to the company</p><p>   ** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price</p><p>   ** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout</p><p>   ** The news on Halozyme might spark a takeover battle, a local trader said</p><p>   ** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps</p><p>($1 = 0.9493 euros)</p><p> (Reporting by Isabel Demetz)</p><p>((Isabel.demetz@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483164323","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483164323","pubTimestamp":1731653010,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** German drug development company Evotec    are seen up around 20% in Lang&Schwarz premarket indications after biotech company Halozyme    made a 2 billion euro buyout offer to the company   ** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price   ** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout   ** The news on Halozyme might spark a takeover battle, a local trader said   ** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","BK4121":"生命科学工具和服务","EVO":"Evotec SE","HALO":"奥洛兹美医疗"},"translate_title":"BUZZ-Evotec接受Halozyme 20亿欧元收购要约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9,"EVO":1},"content_text":"** German drug development company Evotec    are seen up around 20% in Lang&Schwarz premarket indications after biotech company Halozyme    made a 2 billion euro($2.11 billion) buyout offer to the company   ** It said it intends to buy all shares of Evotec at 11 euros per share, which corresponds to a premium of 27.5% as per Thursday closing price   ** On Monday Evotec rose on the news of private investment firm Triton buying over 9% stake in the company and considering a potential buyout   ** The news on Halozyme might spark a takeover battle, a local trader said   ** Evotec said in a statement it will analyze the expression of interest from Halozyme and decide on next steps($1 = 0.9493 euros) (Reporting by Isabel Demetz)((Isabel.demetz@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}